PDF(Pubmed)
Abstract：
BACKGROUND: Neospora caninum is an apicomplexan parasite that is particularly responsible for abortions in cattle and neuromuscular disease in dogs. Due to the limited effectiveness of currently available drugs, there is an urgent need for new therapeutic approaches to control neosporosis. Luciferase-based assays are potentially powerful tools in the search for antiprotozoal compounds, permitting the development of faster and more automated assays. The aim of this study was to construct a luciferase-expressing N. caninum and evaluate anti-N. caninum drugs.
METHODS: Luciferase-expressing N. caninum (Nc1-Luc) was constructed using clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (CRISPR/Cas9). After testing the luciferase expression and phenotype of the Nc1-Luc strains, the drug sensitivity of Nc1-Luc strains was determined by treating them with known positive or negative drugs and calculating the half-maximal inhibitory concentration (IC50). The selective pan-rapidly accelerated fibrosarcoma (pan-RAF) inhibitor TAK-632 was then evaluated for anti-N. caninum effects using Nc1-Luc by luciferase activity reduction assay and other in vitro and in vivo studies.
RESULTS: The phenotypes and drug sensitivity of Nc1-Luc strains were consistent with those of the parental strains Nc1, and Nc1-Luc strains can be used to determine the IC50 for anti-N. caninum drugs. Using the Nc1-Luc strains, TAK-632 showed promising activity against N. caninum, with an IC50 of 0.6131 μM and a selectivity index (SI) of 62.53. In vitro studies demonstrated that TAK-632 inhibited the invasion, proliferation, and division of N. caninum tachyzoites. In vivo studies showed that TAK-632 attenuated the virulence of N. caninum in mice and significantly reduced the parasite burden in the brain.
CONCLUSIONS: In conclusion, a luciferase-expressing N. caninum strain was successfully constructed, which provides an effective tool for drug screening and related research on N. caninum. In addition, TAK-632 was found to inhibit the growth of N. caninum, which could be considered as a candidate lead compound for new therapeutics for neosporosis.
METHODS: Luciferase-expressing N. caninum (Nc1-Luc) was constructed using clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (CRISPR/Cas9). After testing the luciferase expression and phenotype of the Nc1-Luc strains, the drug sensitivity of Nc1-Luc strains was determined by treating them with known positive or negative drugs and calculating the half-maximal inhibitory concentration (IC50). The selective pan-rapidly accelerated fibrosarcoma (pan-RAF) inhibitor TAK-632 was then evaluated for anti-N. caninum effects using Nc1-Luc by luciferase activity reduction assay and other in vitro and in vivo studies.
RESULTS: The phenotypes and drug sensitivity of Nc1-Luc strains were consistent with those of the parental strains Nc1, and Nc1-Luc strains can be used to determine the IC50 for anti-N. caninum drugs. Using the Nc1-Luc strains, TAK-632 showed promising activity against N. caninum, with an IC50 of 0.6131 μM and a selectivity index (SI) of 62.53. In vitro studies demonstrated that TAK-632 inhibited the invasion, proliferation, and division of N. caninum tachyzoites. In vivo studies showed that TAK-632 attenuated the virulence of N. caninum in mice and significantly reduced the parasite burden in the brain.
CONCLUSIONS: In conclusion, a luciferase-expressing N. caninum strain was successfully constructed, which provides an effective tool for drug screening and related research on N. caninum. In addition, TAK-632 was found to inhibit the growth of N. caninum, which could be considered as a candidate lead compound for new therapeutics for neosporosis.
摘要：
背景：新孢子虫是一种根尖丛寄生虫，特别是牛流产和狗神经肌肉疾病的原因。由于目前可用药物的有效性有限，迫切需要新的治疗方法来控制新孢子虫病。基于萤光素酶的检测是寻找抗原生动物化合物的潜在强大工具，允许开发更快、更自动化的检测方法。这项研究的目的是构建一个表达荧光素酶的犬奈米，并评估抗N。caninum药物。
方法：使用成簇的规则间隔短回文重复序列（CRISPR）相关蛋白9（CRISPR/Cas9）构建了表达荧光素酶的犬奈米（Nc1-Luc）。在测试Nc1-Luc菌株的荧光素酶表达和表型后，Nc1-Luc菌株的药物敏感性通过用已知的阳性或阴性药物处理并计算半数最大抑制浓度(IC50)来确定。然后评估选择性泛快速加速纤维肉瘤（pan-RAF）抑制剂TAK-632的抗N。通过荧光素酶活性降低测定和其他体外和体内研究，使用Nc1-Luc对犬的影响。
结果：Nc1-Luc菌株的表型和药物敏感性与亲本菌株Nc1一致，Nc1-Luc菌株可用于确定抗N的IC50。caninum药物。使用Nc1-Luc菌株，TAK-632显示出对犬的有希望的活性，IC50为0.6131μM,选择性指数(SI)为62.53。体外研究表明，TAK-632抑制侵袭，扩散,和犬齿线虫的分裂。体内研究表明，TAK-632可减弱小鼠中犬奈瑟菌的毒力，并显着降低大脑中的寄生虫负担。
结论：结论：成功构建了表达萤光素酶的犬奈瑟菌，为犬奈瑟菌的药物筛选和相关研究提供了有效的工具。此外,发现TAK-632可以抑制犬的生长，它可以被认为是新孢子虫病新疗法的候选先导化合物。
方法：使用成簇的规则间隔短回文重复序列（CRISPR）相关蛋白9（CRISPR/Cas9）构建了表达荧光素酶的犬奈米（Nc1-Luc）。在测试Nc1-Luc菌株的荧光素酶表达和表型后，Nc1-Luc菌株的药物敏感性通过用已知的阳性或阴性药物处理并计算半数最大抑制浓度(IC50)来确定。然后评估选择性泛快速加速纤维肉瘤（pan-RAF）抑制剂TAK-632的抗N。通过荧光素酶活性降低测定和其他体外和体内研究，使用Nc1-Luc对犬的影响。
结果：Nc1-Luc菌株的表型和药物敏感性与亲本菌株Nc1一致，Nc1-Luc菌株可用于确定抗N的IC50。caninum药物。使用Nc1-Luc菌株，TAK-632显示出对犬的有希望的活性，IC50为0.6131μM,选择性指数(SI)为62.53。体外研究表明，TAK-632抑制侵袭，扩散,和犬齿线虫的分裂。体内研究表明，TAK-632可减弱小鼠中犬奈瑟菌的毒力，并显着降低大脑中的寄生虫负担。
结论：结论：成功构建了表达萤光素酶的犬奈瑟菌，为犬奈瑟菌的药物筛选和相关研究提供了有效的工具。此外,发现TAK-632可以抑制犬的生长，它可以被认为是新孢子虫病新疗法的候选先导化合物。
